Ernexa Therapeutics Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
Ernexa Therapeutics Inc. (ERNA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $21.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2026-03-13
- Ernexa Therapeutics Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2025 was $21.00K, a 12.50% decline from fiscal 2024.
- Ernexa Therapeutics Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2024 was $24.00K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month |
|---|---|
| 2025-12-31 | $21.00K 10-K · filed 2026-03-13 |
| 2024-12-31 | $24.00K 10-K · filed 2026-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |